


Status: Currently Official on 14-Feb-2025
 Official Date: Official as of 01-May-2020
 Document Type: USP Monographs
 DocId: GUID-122E88CB-90EF-483E-9C1C-37A4C2802CB9_2_en-US
 DOI: https://doi.org/10.31003/USPNF_M33670_02_01
 DOI Ref: ich8q

© 2025 USPC
 Do not distribute

Fluorometholone



$C_{22}H_{29}FO_4$ 376.46

Pregna-1,4-diene-3,20-dione, 9-fluoro-11,17-dihydroxy-6-methyl-, (6 α ,11 β)-;

9-Fluoro-11 β ,17-dihydroxy-6 α -methylpregna-1,4-diene-3,20-dione CAS RN[®]: 426-13-1; UNII: SV0CSG527L.

DEFINITION

Fluorometholone contains NLT 97.0% and NMT 103.0% of fluorometholone ($C_{22}H_{29}FO_4$), calculated on the dried basis.

IDENTIFICATION

Change to read:

- A. Δ [SPECTROSCOPIC IDENTIFICATION TESTS \(197\), Infrared Spectroscopy: 197K](#) Δ (CN 1-MAY-2020)
- B. The retention time of the major peak of the *Sample solution* corresponds to that of the *Standard solution*, as obtained in the Assay.

ASSAY

• PROCEDURE

Mobile phase: Mix 425 g (538 mL) of methanol and 400 g (400 mL) of water. Adjust with phosphoric acid to a pH of 2.4.

Standard stock solution: 0.25 mg/mL of [USP Fluorometholone RS](#) prepared as follows. Transfer a suitable amount of [USP Fluorometholone RS](#) to a suitable volumetric flask and dissolve in 2% of the final volume of tetrahydrofuran. Dilute with *Mobile phase* to volume.

Standard solution: 50 μ g/mL of [USP Fluorometholone RS](#) in *Mobile phase* from *Standard stock solution*

Sample stock solution: 0.25 mg/mL of Fluorometholone prepared as follows. Transfer a suitable amount of Fluorometholone to a suitable volumetric flask and dissolve in 2% of the final volume of tetrahydrofuran. Dilute with *Mobile phase* to volume.

Sample solution: 50 μ g/mL of Fluorometholone in *Mobile phase* from *Sample stock solution*

Chromatographic system

(See [Chromatography \(621\), System Suitability](#).)

Mode: LC

Detector: UV 240 nm

Column: 4.6-mm \times 25-cm; 5- μ m packing L1

Flow rate: 0.6 mL/min

Injection volume: 20 μ L

Run time: NLT 1.6 times the retention time of fluorometholone

System suitability

Sample: *Standard solution*

Suitability requirements

Tailing factor: NMT 1.3

Relative standard deviation: NMT 0.73%

Analysis

Samples: *Standard solution* and *Sample solution*

Calculate the percentage of fluorometholone ($C_{22}H_{29}FO_4$) in the portion of Fluorometholone taken:

$$\text{Result} = (r_u/r_s) \times (C_s/C_u) \times 100$$

r_u = peak response of fluorometholone from the *Sample solution*

r_s = peak response of fluorometholone from the *Standard solution*

C_s = concentration of [USP Fluorometholone RS](#) in the *Standard solution* (µg/mL)

C_u = concentration of Fluorometholone in the *Sample solution* (µg/mL)

Acceptance criteria: 97.0%–103.0% on the dried basis

IMPURITIES

- [RESIDUE ON IGNITION \(281\)](#): NMT 0.2%

ORGANIC IMPURITIES

Mobile phase: Proceed as directed in the Assay.

System suitability stock solution: 0.5 mg/mL each of [USP Fluorometholone RS](#) and [USP Fluorometholone Related Compound A RS](#) prepared as follows. Transfer a suitable amount of [USP Fluorometholone RS](#) and [USP Fluorometholone Related Compound A RS](#) to a suitable volumetric flask and dissolve in 4% of the final volume of tetrahydrofuran. Dilute with *Mobile phase* to volume.

System suitability solution: 0.005 mg/mL each of [USP Fluorometholone RS](#) and [USP Fluorometholone Related Compound A RS](#) in *Mobile phase* from *System suitability stock solution*

Standard stock solution: 0.5 mg/mL of [USP Fluorometholone RS](#) prepared as follows. Transfer a suitable amount of [USP Fluorometholone RS](#) to a suitable volumetric flask and dissolve in 4% of the final volume of tetrahydrofuran. Dilute with *Mobile phase* to volume.

Standard solution: 0.5 µg/mL of [USP Fluorometholone RS](#) in *Mobile phase* from *Standard stock solution*

Sample solution: 0.5 mg/mL of Fluorometholone prepared as follows. Transfer a suitable amount of Fluorometholone to a suitable volumetric flask and dissolve in 4% of the final volume of tetrahydrofuran. Dilute with *Mobile phase* to volume.

Chromatographic system: Proceed as directed in the Assay except for the *Run time*.

Run time: NLT 2.1 times the retention time of fluorometholone

System suitability

Samples: *System suitability solution* and *Standard solution*

Suitability requirements

Resolution: NLT 3 between fluorometholone and fluorometholone related compound A, *System suitability solution*

Relative standard deviation: NMT 5.0%, *Standard solution*

Analysis

Samples: *Standard solution* and *Sample solution*

Calculate the percentage of each impurity in the portion of Fluorometholone taken:

$$\text{Result} = (r_u/r_s) \times (C_s/C_u) \times 100$$

r_u = peak response of each impurity from the *Sample solution*

r_s = peak response of fluorometholone from the *Standard solution*

C_s = concentration of [USP Fluorometholone RS](#) in the *Standard solution* (mg/mL)

C_u = concentration of Fluorometholone in the *Sample solution* (mg/mL)

Acceptance criteria: See [Table 1](#). Disregard any peaks below 0.02%.

Table 1

Name	Relative Retention Time	Acceptance Criteria, NMT (%)
Fluorometholone	1.0	—
Fluorometholone related compound A	1.2	0.5
Individual unspecified impurities	—	0.10
Total impurities	—	1.0

SPECIFIC TESTS

- [OPTICAL ROTATION, Specific Rotation\(781S\)](#).

Sample solution: 10 mg/mL in dimethyl sulfoxide

Acceptance criteria: +62° to +70°

- [LOSS ON DRYING \(731\)](#).

Analysis: Dry under vacuum at 60° for 3 h.

Acceptance criteria: NMT 1.0%

ADDITIONAL REQUIREMENTS

- **PACKAGING AND STORAGE:** Preserve in tight, light-resistant containers.

- **USP REFERENCE STANDARDS (11)**

[USP Fluorometholone RS](#)

[USP Fluorometholone Related Compound A RS](#)

11 β ,17 α -Dihydroxy-6 α -methylpregna-1,4-diene-3,20-dione.

$C_{22}H_{30}O_4$ 358.47

Auxiliary Information - Please [check for your question in the FAQs](#) before contacting USP.

Topic/Question	Contact	Expert Committee
FLUOROMETHOLONE	Documentary Standards Support	SM52020 Small Molecules 5

Chromatographic Database Information: [Chromatographic Database](#)

Most Recently Appeared In:

Pharmacopeial Forum: Volume No. PF 41(2)

Current DocID: GUID-122E88CB-90EF-483E-9C1C-37A4C2802CB9_2_en-US

DOI: https://doi.org/10.31003/USPNF_M33670_02_01

DOI ref: [ich8q](#)

OFFICIAL